Product image of Pandemic Influenza Vaccine H5n1 Astrazeneca (A/Vietnam/1203/2004 (H5n1) Strain (A/Vietnam/1203/2004, Medi 0141000136)) supplied by GNH India

Pandemic Influenza Vaccine H5n1 Astrazeneca

Active Ingredient:
A/Vietnam/1203/2004 (H5n1) Strain (A/Vietnam/1203/2004, Medi 0141000136)
Origin:
EU

Pandemic Influenza Vaccine H5n1 Astrazeneca (A/Vietnam/1203/2004 (H5n1) Strain (A/Vietnam/1203/2004, Medi 0141000136))

A/Vietnam/1203/2004 (H5N1) strain, the active ingredient in Pandemic Influenza Vaccine H5n1 Astrazeneca, is a vaccine presented as a nasal spray for nasal use. It is intended to prevent pandemic influenza caused by the H5N1 virus in individuals at risk of exposure.

GNH India supplies Pandemic Influenza Vaccine H5n1 Astrazeneca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. The company adheres to Good Distribution Practice standards and provides cold‑chain logistics for temperature‑sensitive biologics.

Manufacturer / TM Owner

Astrazeneca Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Pandemic Influenza Vaccine H5n1 Astrazeneca is an influenza vaccine used to prevent infection by H5N1 pandemic strains.

  • Pandemic influenza (H5N1): induces protective immunity to reduce the risk of infection.
  • Close contacts of confirmed H5N1 cases: provides prophylactic protection for exposed individuals.
  • Travelers to endemic regions: helps prevent H5N1 exposure during travel.

How It Works

  • The vaccine contains inactivated A/Vietnam/1203/2004 (H5N1) viral antigens delivered as a nasal spray. Upon administration, the antigens are taken up by mucosal immune cells, stimulating both local IgA and systemic IgG antibody production, as well as cellular immune responses, thereby preparing the host to neutralize the H5N1 virus on exposure.

Side Effects

Common adverse reactions are generally mild and resolve without intervention.

Common Side Effects

  • Nasal congestion or irritation.
  • Sore throat.
  • Mild fever.
  • Headache.
  • Runny nose.
  • Transient cough.

Serious or Rare Side Effects

  • Anaphylactic reaction.
  • Severe allergic response (e.g., angioedema).
  • Guillain‑Barré syndrome.
  • Neurological events such as seizures.
  • High‑grade fever persisting >48 hours.
  • Thrombocytopenia.

Precautions & Warnings

Vaccination should be considered in the context of individual health status and potential contraindications.

  • Pregnancy: safety not established; consult a healthcare professional before use.
  • Immunocompromised patients: may exhibit reduced immune response.
  • Egg allergy: assess risk as the vaccine may contain trace egg proteins.
  • Recent receipt of another vaccine: separate administration by at least 14 days.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccines may interact with other biologics or immunomodulating agents, affecting efficacy or safety.

Major Interactions (Avoid)

  • Intravenous immunoglobulin (IVIG): can diminish vaccine‑induced immunity.
  • Live viral vaccines administered concurrently: may interfere with immune response.
  • Antiviral agents (e.g., oseltamivir) given within 48 hours of vaccination: may reduce immunogenicity.

Moderate Interactions (Monitor Closely)

  • Immunosuppressive drugs (e.g., methotrexate): may lower antibody production.
  • Systemic corticosteroids: could affect vaccine effectiveness.
  • Antihistamines: may mask mild allergic reactions post‑vaccination.

Frequently Asked Questions

Pandemic Influenza Vaccine H5n1 Astrazeneca is used to prevent infection caused by the H5N1 avian influenza virus. It is administered as a nasal spray to induce immunity in individuals who may be exposed to pandemic strains, helping to reduce the risk of severe disease.

The A/Vietnam/1203/2004 (H5N1) strain provides viral antigens that are recognized by the immune system when delivered nasally. This triggers both mucosal and systemic immune responses, leading to the production of antibodies and cellular immunity that can neutralize the H5N1 virus upon future exposure.

The specific dosing regimen for Pandemic Influenza Vaccine H5n1 Astrazeneca is determined by the prescribing healthcare professional based on regulatory guidance, patient age, and risk factors. The prescriber will decide the appropriate number of doses and interval between administrations.

Safety data for use of this vaccine during pregnancy or while breastfeeding are limited. Healthcare providers should evaluate the potential benefits and risks on an individual basis and discuss any concerns with the patient before administration.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Pandemic Influenza Vaccine H5n1 Astrazeneca is a nasal spray formulation, whereas many alternative H5N1 vaccines are administered intramuscularly. The nasal route targets mucosal immunity, which may offer additional protection at the entry site of the virus, but overall efficacy and safety profiles are comparable when used as recommended.

The vaccine must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. It should be kept in the original packaging until use to maintain stability and potency.

Pandemic Influenza Vaccine H5n1 Astrazeneca is administered as a single dose nasal spray. The patient tilts the head back slightly, inserts the applicator into each nostril, and delivers the prescribed volume as instructed by the healthcare professional.

Serious risks, although rare, include anaphylaxis, severe allergic reactions, Guillain‑Barré syndrome, and other neurological events. Recipients should be observed for a short period after vaccination and seek immediate medical attention if signs of a severe reaction develop.

Individuals with a known severe allergy to any component of the vaccine, including egg proteins, should not receive it. Those who have experienced a previous severe reaction to an H5N1 vaccine or who have contraindications identified by their healthcare provider should also avoid this vaccine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing A/Vietnam/1203/2004 (H5n1) Strain (A/Vietnam/1203/2004, Medi 0141000136)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT